CDR 813
Alternative Names: CDR-813Latest Information Update: 20 Sep 2024
At a glance
- Originator CDR-Life
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours